Get the Stockscreener App
5.88
3.61%
-0.2201
Pre-market:
5.60
-0.28
-4.76%
Decoy Therapeutics Inc stock is traded at $5.88, with a volume of 4,331.
It is down -3.61% in the last 24 hours and up +33.33% over the past month.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
See More
Previous Close:
$6.1001
Open:
$6.31
24h Volume:
4,331
Relative Volume:
0.29
Market Cap:
$3.13M
Revenue:
-
Net Income/Loss:
$-13.03M
P/E Ratio:
-0.0474
EPS:
-124.0371
Net Cash Flow:
$-6.53M
1W Performance:
+6.72%
1M Performance:
+33.33%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.5001
$6.31
1-Week Range:
$5.29
$6.55
52-Week Range:
$4.3201
$16.92
Decoy Therapeutics Inc Stock (DCOY) Company Profile
Name
Decoy Therapeutics Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
5.88 | 3.25M | 0 | -13.03M | -6.53M | -124.04 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-26 | Initiated | Ladenburg Thalmann | Buy |
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc Stock (DCOY) Latest News
Decoy Therapeutics: David Arthur Completing His Service on the Board >DCOY - Moomoo
Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London - PR Newswire
[RW] Decoy Therapeutics Inc. SEC Filing - Stock Titan
DCOY | Decoy Therapeutics Inc. Common Executive Compensation - Quiver Quantitative
Decoy Therapeutics (DCOY) details 2026 director, pay and auditor votes - Stock Titan
DCOY Q3 2024 Earnings: Narrower-Than-Expected Loss Fails to Offset Investor ConcernsSpecial Dividend Alert - newsline.com
Decoy Therapeutics nominates Patricia Gauthier to board - Investing.com UK
Decoy Therapeutics nominates Patricia Gauthier to board By Investing.com - Investing.com South Africa
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors - PR Newswire
hVIVO win with Decoy Therapeutics signals shift towards broader contract research market, says broker - Proactive Investors
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Ca - GuruFocus
hVIVO signs consultancy deal with antiviral developer Decoy Therapeutics - Proactive Investors
hVIVO to support Decoy Therapeutics respiratory antiviral development - Vox Markets
hVIVO signs consultancy deal with Decoy Therapeutics By Investing.com - Investing.com Canada
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic - Financial Times
HVIVO plc Signs Consultancy Contract With Decoy Therapeutics - marketscreener.com
Decoy Therapeutics (DCOY) Surges 10.75%: Is Momentum Building for the Biotech Stock?ATR Stop - The Legal Advocate
Decoy Therapeutics names MIT professor as advisory board chair - Investing.com
Decoy Therapeutics names MIT professor as advisory board chair By Investing.com - Investing.com Canada
Decoy Therapeutics Inc. Announces Appointment of Brad L. Pentelute as Chair of Scientific Advisory Board - marketscreener.com
Decoy Therapeutics (DCOY) Surges 13.5%: Testing Key Resistance at $7.67Modified Schiff - The Legal Advocate
Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
DCOY Sets May 22 Vote, Puts Focus Back on Thinly Traded Stock - Bez Kabli
hVIVO to host capital markets day as it pitches broader clinical development role - Yahoo Finance UK
Decoy Therapeutics Sets 2026 Annual Shareholder Meeting Date - TipRanks
Decoy Therapeutics sets date for 2026 annual meeting and proposal deadlines - Investing.com Australia
Number of shareholders of Decoy Therapeutics Inc. – NASDAQ:DCOY - TradingView
Decoy Therapeutics outlines antiviral pipeline milestones By Investing.com - Investing.com Nigeria
Certain Restricted Stock Units of Decoy Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2026. - marketscreener.com
Certain Stock Options of Decoy Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2026. - marketscreener.com
1,051,782 Common Stock of Decoy Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2026. - marketscreener.com
Decoy Therapeutics Inc. 2026 Q1 10-Q Filing: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Decoy Therapeutics: Q1 Earnings Snapshot - KTEN
Decoy Therapeutics Inc. 1Q 2026: Net loss $(2.22M), EPS $(4.18) — 10-Q Summary - TradingView
Decoy Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
DCOY Q1'26 Earnings: EPS estimate is (4.12) USD - TradingView
Decoy Therapeutics to implement 1-for-12 reverse stock split - Investing.com
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston - BioSpace
Decoy Therapeutics (DCOY) Proxy Filing Summary - Quartr
Decoy Therapeutics Inc (FRA:FP11) Stock PDF (Updated: 2026/04/27) - GuruFocus
Decoy Therapeutics Showcases Novel Antiviral Therapies in Boston - Intellectia AI
Decoy Therapeutics Inc (FRA:FP11) Stock Earnings Transcripts - GuruFocus
Salarius Pharmaceuticals stock tumbles after announcing $7 million discounted public offering - MSN
Decoy Therapeutics Inc Stock (DCOY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Decoy Therapeutics Inc Stock (DCOY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HANISH ARNOLD C | Director |
Dec 30 '25 |
Sale |
0.64 |
12 |
8 |
0 |
| HANISH ARNOLD C | Director |
Nov 20 '25 |
Buy |
0.75 |
5,000 |
3,740 |
5,015 |
| Rosenblum Mark J | Exec VP Finance, CFO |
Nov 20 '25 |
Buy |
0.80 |
20,000 |
16,000 |
20,177 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):